NCT05278325 (TeII) is a NA clinical trial of Telephone intervention in Migraine, sponsored by Danish Headache Center.

Who is sponsoring NCT05278325?

NCT05278325 is sponsored by Danish Headache Center.

What drugs are being tested in NCT05278325?

Interventions in NCT05278325: Telephone intervention.

What condition does NCT05278325 study?

NCT05278325 studies Migraine, Tension-Type Headache.

Is NCT05278325 still recruiting?

NCT05278325 is currently completed. Last updated 14 March 2022.

Last reviewed 2022-03-14 · How we verify

NCT05278325: TeII

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Improved Treatment Course for Patients With Migraine and Tension-type Headache

Completed NA Last updated 14 March 2022

What this trial tests

NA trial testing Telephone intervention in Migraine in 187 participants. Completed in 5 October 2021.

Timeline

1 May 2020

Primary endpoint
1 April 2021

5 October 2021

Quick facts

Lead sponsor	Danish Headache Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	187
Start date	1 May 2020
Primary completion	1 April 2021
Estimated completion	5 October 2021
Sites	1 location across Denmark

Drugs / interventions tested

Telephone intervention

Conditions studied

Migraine — all drugs for Migraine →
Tension-Type Headache — all drugs for Tension-Type Headache →

Sponsor

Danish Headache Center — full company profile →

Who can join

18 and older, any sex, with Migraine or Tension-Type Headache. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to improve treatment for newly referred patients with migraine and tension-type headache to the Danish Headache Center. All patients will recieve an electronic questionnaire just before the first visit concerning their current and previous history of headache and headache treatment. Half of them will enter a special telephone-intervention (TeII) program with two planned phone-calls after 8 and 16 weeks from first visit. The other half of patients will follow the normal follow-up program. All patients will be seen by a headache specialist after 6 months and will be asked to fill in a follow-up electronic questionnaire.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Telephone follow-up on treatment and patient satisfaction at a Danish tertiary headache center: A prospective study.
Carlsen LN, Bendtsen L, Jensen RH, Schytz HW. · · 2022 · cited 5× · PMID 36373785 · DOI 10.1111/head.14405

Verify or expand the search:

Other recruiting trials for Migraine

Currently open trials in the same condition.

NCT07419607 — MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducat · NA · recruiting
NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
NCT07343427 — Impact of GON PRF on Central Sensitization in Migraine Patients · NA · active not recruiting
NCT07336056 — Nerivio Efficacy Under High-Frequency Use · Phase 4 · active not recruiting
NCT07385755 — Desvenlafaxine for Preventive Treatment of Frequent Migraines · NA · active not recruiting

Other Danish Headache Center trials

Trials by the same sponsor.

NCT07451769 — Selective Activation of the Adrenomedullin Receptors in Migraine · NA · not yet recruiting
NCT07342296 — Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38 · NA · not yet recruiting
NCT07059546 — Hypersensitivity to Adrenomedullin in Post-Traumatic Headache · NA · recruiting
NCT07021859 — Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide · NA · recruiting
NCT06959004 — Substance P-Induced Migraine Attacks Without Aura · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05278325 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Danish Headache Center
Last refreshed: 14 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05278325.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing